Key learning points
- Spirometry remains the method of choice for confirming a diagnosis of COPD in patients who have appropriate signs and symptoms along with a recent chest X-ray and full blood count.
- LABA and LAMA dual therapy has the greatest benefit to patients without asthmatic features or features suggesting steroid responsiveness who remain breathless or have exacerbations on a SABA
- Inhaled corticosteroids and a LABA should be considered for patients with asthmatic features or features suggesting steroid responsiveness whose symptoms are not controlled on a SABA
The NICE guideline on the diagnosis and management of COPD was partially updated in December 2018 and replaces the previous version published in 2010. Most people with COPD in the UK do not receive a diagnosis until they are over 50, therefore the guideline aims to ‘help people with COPD to receive a diagnosis earlier so that they can benefit from treatments to reduce symptoms, improve quality of life and keep them healthy for longer’. 1
The 2018 version gives updated recommendations on diagnosis and prognosis. It covers inhaled combination therapy, prophylactic antibiotic therapy, oxygen therapy as well as managing pulmonary hypertension and cor pulmonale. There is a section on lung surgery and lung volume reduction procedures, and self-management, education and telehealth monitoring.
This article will focus on the main changes of note for those working in primary care relating to the diagnosis and pharmacological management of COPD, but does not attempt to cover all updates to the guidance.
Not much has changed in the recommendations for diagnosis, which should be based on a compatible history along with examination, a recent chest X-ray and full blood count , with spirometry as the gold standard test for confirming the diagnosis..2 It is concerning therefore that a recent study found that many patients had been wrongly diagnosed with COPD because they had not had spirometry testing and were prescribed COPD medication, often inhaled corticosteroids, unnecessarily.3
A somewhat controversial addition is the recommendation that patients should be referred to primary care for respiratory review and spirometry when an incidental finding of suspected COPD is found on a chest X-ray or CT scan.1 Although the more cases of COPD that are picked up at an early stage the better, not all GPs receive payment for spirometry in their contract and extra referrals may increase their workload when a patient is already under the care of the hospital.4
The use of multidimensional indices to assess prognosis are not recommended at this time. However, the factors associated with prognosis are listed and may be used to help guide discussions about a patient’s prognosis and treatment options (Box 1).
Box 1. Prognostic factors for patients with stable COPD1
- Smoking status
- Breathlessness (MRC scale)
- Chronic hypoxia and/or cor pulmonale
- Low BMI
- Severity and frequency of exacerbations
- Hospital admissions
- Symptom burden (eg COPD Assessment Test score)
- Exercise capacity (eg 6-minute walk test)
- TLCO (gas transfer) test
- Whether the person meets the criteria for long-term oxygen therapy and/or home non-invasive ventilation
NICE has produced a useful visual summary to accompany the guideline, which clearly outlines recommended non-pharmacological management and use of inhaled therapies for patients diagnosed with COPD (Figure 1).5
Figure 1. Non-pharmacological management and use of inhaled therapies
Patients who require inhaled therapy should be treated initially with short-acting bronchodilators (SABAs) as needed. If they are still breathless or have exacerbations, their treatment should then be guided by whether or not they have asthmatic features/features suggesting steroid responsiveness (a previous secure diagnosis of asthma or atopy, a higher blood eosinophil count, substantial variation in FEV1 over time of at least 400 ml or substantial diurnal variation in peak expiratory flow of at least 20%).1,5
Patients without asthmatic features/features suggesting steroid responsiveness should be offered dual therapy with a long-acting muscarinic antagonist (LAMA) and a long-acting beta2 agonist (LABA). This combination has been shown to provide the greatest benefit to patients’ overall quality of life, while being the most cost-effective option.1,5
For patients who have asthmatic features/features suggesting steroid responsiveness, a LABA together with an inhaled corticosteroid (ICS) should be considered. If patients still remain breathless or have further exacerbations on this combination, a LAMA can be offered in addition.1,5
However, if a patient’s symptoms are currently well controlled on a different regimen, such as LABA or LAMA monotherapy, they do not need to change to the recommended regimen until a change in their condition necessitates it.1
For all inhaled therapies, it is recommended to keep the number and type of inhalers a patient uses to a minimum, as well as ensure that their prescription specifies the brand and inhaler they have been trained to use.1
This project was initiated and funded by Teva Respiratory. Teva have had no influence over content. Topics and content have been selected and written by independent experts.
This Let’s Talk Knowledge article has been created in collaboration with the Editorial Board. The Board select topics, content, as well as independent experts to create the content and this process is supported by Haymarket Media Group. Click here to learn more about the content development process.